Filing Flows › Comparisons › BIOA vs DNTH
BioAge Labs vs Dianthus Therapeutics: BIOA and DNTH compared
BioAge Labs is the larger company: $298K of revenue in its latest quarter (Q3 2026) against $284K for Dianthus Therapeutics (Q4 2025). Dianthus Therapeutics is growing faster (-79% against -86% a year earlier).
Where the money goes: BIOA and DNTH
BioAge Labs (BIOA) · Q3 2026
BioAge Labs, Q3 2026: revenue $298K (-86% year over year), net loss $33.5M, operating cash flow −$31.0M. The chart follows the revenue to costs, profit and cash.
Dianthus Therapeutics (DNTH) · Q4 2025
Dianthus Therapeutics, Q4 2025: revenue $284K (-79% year over year), net loss $64.4M, operating cash flow −$47.0M. The chart follows the revenue to costs, profit and cash.
| BioAge Labs (BIOA) | Dianthus Therapeutics (DNTH) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q4 2025 |
| Revenue | $298K | $284K |
| Revenue growth, Y/Y | -86% | -79% |
| Operating margin | n/m | n/m |
| Net earnings | −$33.5M | −$64.4M |
| Operating cash flow | −$31.0M | −$47.0M |
Questions
Which is bigger, BioAge Labs or Dianthus Therapeutics?
BioAge Labs is the larger company: $298K of revenue in its latest quarter (Q3 2026) against $284K for Dianthus Therapeutics (Q4 2025).
Is BioAge Labs or Dianthus Therapeutics growing faster?
Dianthus Therapeutics is growing faster (-79% against -86% a year earlier).
More: BioAge Labs earnings · how BioAge Labs makes money · Dianthus Therapeutics earnings · how Dianthus Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-K filed Mar 9, 2026). Fiscal quarters can end on different dates. Not investment advice.